{
  "folder": "IC-127",
  "content": "{{knowledge objective\n|Identifiant=OIC-127-08-B\n|Item_parent=Benign prostatic hypertrophy\n|Item_parent_short=Benign prostatic hypertrophy\n|Rank=B\n|Intitle=Know the principles of treatment: abstention-surveillance - pharmacological treatment - surgical treatment\n|Description=None\n|Rubric=Management\n|Contributors=Alexandre Ingels, Jonathan Olivier\n|Order=8}}\n\n\n=='''Abstention-surveillance:'''==\nFor patients with uncomplicated BPH (acute or chronic retention, renal failure, calculi, infection) and minimal or moderate SBAU with no impairment of quality of life (IPSS score < 9).\n\n*There is a low risk of complications in BPH that is correctly monitored.\n*Patients should be informed that BPH is benign.\n*Clear explanations about BPH should be given to the patient, as this can lead to significant improvement in UABS.\n*Hygienic dietary advice (insufficient to alter the natural history of the disease) has a moderate impact on the evolution of symptoms.\n\n=='''Pharmacological treatments:'''==\nFor patients with uncomplicated BPH and moderate to severe LUTS (IPSS score >9)\n\n*<Phytotherapy:</u> **Their mode of action remains unknown.\n**Their mode of action remains unknown\n**Well tolerated\n**Lower level of recommendation than other pharmacological classes.\n*<Alpha-receptor blockers\n*Improves urinary flow by relaxing the smooth muscles of the prostate and bladder neck.\n**Rapid and stable action over time\n**Undesirable effects: orthostatic hypotension, [[Genital-scrotal pathology in boys and men|anejaculation 58]]\n**In cases of urinary retention, prescription of alpha-blockers 48 hours before attempting to remove the bladder catheter improves the chances of successfully resuming good quality micturition.\n*<5\u03b1-reductase inhibitors (5-ARIs)</u>.\n**Proposed to patients with bothersome SBAU (IPSS > 8) with a prostatic volume >40ml\n**Blocks the conversion of testosterone to dihydrotestosterone\n**Improves urinary output by reducing prostate volume, resulting in a 50% reduction in PSA after 6 months.\n**Take effect over several months\n**May be used as a second-line treatment after failure of monotherapy with phytotherapy or alpha-blockers.\n**Undesirable effects: erectile dysfunction, asthenia.\n**The 5 ARIs are thought to increase the risk of high-risk prostate cancer.\n*<Combination of alpha-blockers and 5\u03b1-reductase inhibitors</u>.\n**Therapy more effective than either treatment alone.\n**Adverse effects of the 2 treatments combined.\n**Recommended in the event of ineffectiveness of treatments taken as monotherapy.\n*<Phosphodiesterase type 5 inhibitors (tadalafil)\n**May be offered to patients with bothersome LUTS who also have erectile dysfunction.\n**Undesirable effects: hot flushes.\n**Cardiological opinion should be sought in patients who are not very active or who have cardiovascular risk factors.\n*<Anticholinergics</u>.\n**In combination with an alpha-blocker in the event of persistent storage symptoms under alpha -blocker.\n**Contraindicated in cases of post-micturition residue > 150ml and untreated acute angle-closure glaucoma.\n**Undesirable effects: constipation, dry mouth, worsening of dysuria, cognitive disorders (elderly subjects).\n\n=='''Surgical treatment:'''==\nFor patients with complicated BPH (acute urine retention, bladder lithiasis, recurrent haematuria of prostatic origin, [[Chronic renal failure in adults and children|chronic obstructive renal failure 264]], [[Urinary infections in children and adults|recurrent infections 161]]) or moderate to severe UABS resistant to maximal medical treatment.\n\n*Allow removal of subvesical obstruction\n*<u>Ablative treatments:</u>\n**Transurethral resection of the prostate (mono or bi-polar) (prostatic volume <80cc)\n**Endoscopic enucleation of prostate adenoma (lasers, bi-polar resector) (No prostate volume limit)\n**Prostate vaporisation (lasers, bi-polar resectorator) (No prostate volume limit)\n**Prostatic adenomectomy by suprapubic laparotomy (prostatic volume >80cc)\n*<Non-ablative treatments:</u> **Cervico-prostatic incision\n**Cervico-prostatic incision (prostatic volume <30cc)\n**Urethral implants (Urolift\u00ae) (prostate volume <80cc)\n\n==All these treatments to relieve BPH obstruction carry risks of:==\n\n*urinary incontinence\n*retrograde ejaculation\n*urinary tract infections\n*urethral stricture",
  "question": {
    "question": "Which of the following is NOT a potential risk associated with the surgical treatment of BPH obstructions?",
    "option_a": "Urinary incontinence",
    "option_b": "Retrograde ejaculation",
    "option_c": "Chronic obstructive pulmonary disease",
    "option_d": "Urethral stricture",
    "correct_option": "C"
  }
}